PERIOPERATIVE TREATMENT WITH COI-B (CAPECITABINE, OXALIPLATIN, IRINOTECAN AND BEVACIZUMAB) OF HIGH RISK OR BORDERLINE RESECTABLE COLORECTAL CANCER LIVER METASTASES
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Study ID
- NCT02086656
- Phase
- PHASE2
- Status
- Completed
Conditions
- Colorectal Cancer Liver Metastases
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- capecitabine, oxaliplatin, irinotecan and bevacizumab — DRUGperioperative COI-B
Study Details
Capecitabine, oxaliplatin, irinotecan and bevacizumab as perioperative strategy of borderline and/or high risk resectable colorectal cancer liver metastases
Key Dates
- Start date
- Jun 30, 2013
- Status verified
- Aug 2019
- Primary completion
- Mar 30, 2017
- Completion
- Mar 30, 2017
Study Design
- Enrollment
- 46 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: open labelSingle arm, open label
Primary Outcome Measure
Pathological response rate [ Time Frame: Assessed at the time of surgery of liver metastases (between weeks 17-20 from enrollment) ]